ISORDIL Drug Patent Profile
✉ Email this page to a colleague
When do Isordil patents expire, and when can generic versions of Isordil launch?
Isordil is a drug marketed by Wyeth Ayerst, Bausch, and Biovail. and is included in three NDAs.
The generic ingredient in ISORDIL is isosorbide dinitrate. There are thirty-seven drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the isosorbide dinitrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Isordil
A generic version of ISORDIL was approved as isosorbide dinitrate by PAR PHARM on March 12th, 1987.
Summary for ISORDIL
US Patents: | 0 |
Applicants: | 3 |
NDAs: | 3 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 67 |
Clinical Trials: | 6 |
Patent Applications: | 3,873 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ISORDIL |
What excipients (inactive ingredients) are in ISORDIL? | ISORDIL excipients list |
DailyMed Link: | ISORDIL at DailyMed |
Recent Clinical Trials for ISORDIL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Children's Hospital Medical Center, Cincinnati | Phase 2 |
Brigham and Women's Hospital | Phase 4 |
Momentum Research, Inc. | Phase 3 |
Pharmacology for ISORDIL
Drug Class | Nitrate Vasodilator |
Physiological Effect | Vasodilation |